Vinorelbine plus low-dose cisplatinum with concomitant radiotherapy for the treatment of locally advanced or inoperable non-metastasized non-small-cell lung cancer (stage I-IIIB): a phase II study

Ralph Winterhalder; Simone Deschler-Marini; Christine Landmann; Roger Kann; Jakob Passweg; Richard Herrmann; Miklos Pless

doi:10.1016/j.radonc.2004.06.009

Vinorelbine plus low-dose cisplatinum with concomitant radiotherapy for the treatment of locally advanced or inoperable non-metastasized non-small-cell lung cancer (stage I-IIIB): a phase II study

Radiother Oncol. 2004 Dec;73(3):321-4. doi: 10.1016/j.radonc.2004.06.009.

Authors

Ralph Winterhalder¹, Simone Deschler-Marini, Christine Landmann, Roger Kann, Jakob Passweg, Richard Herrmann, Miklos Pless

Affiliation

¹ Department of Oncology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland.

PMID: 15588877
DOI: 10.1016/j.radonc.2004.06.009

Abstract

In a phase II study, we assessed the toxicity and efficacy of daily low-dose cisplatin (6 mg/m2) and weekly vinorelbine (15 mg/m2) with concurrent thoracic irradiation (60 Gy) for locally advanced non-metastasized non-small-cell lung cancer. The overall response rate was 65%, complete response 12% and the median overall survival was 64 weeks.

Publication types

Clinical Trial
Clinical Trial, Phase II

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Carcinoma, Non-Small-Cell Lung / radiotherapy*
Cisplatin / administration & dosage
Combined Modality Therapy
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Lung Neoplasms / radiotherapy*
Male
Middle Aged
Survival Analysis
Treatment Outcome
Vinblastine / administration & dosage
Vinblastine / analogs & derivatives*
Vinorelbine

Substances

Vinblastine
Cisplatin
Vinorelbine